The Critical Path Institute (C-Path), a global public-private partnership in response to the FDA’s Critical Path Initiative, today announced the election of Aitia CEO and Founder Colin Hill to its Board of Directors. “Colin has a record of turning complex data into decisions teams can act on,” said Wainwright Fishburn, chairman of the board at C-Path. “He understands how to build companies and tools that support the hard choices in development, and that experience will serve our mission.”
“My entire career – including our work at Aitia – has been dedicated to building a deep understanding of complex disease biology as the best approach to effective drug discovery and development,” said Hill. “I am honored to bring that focus to the C-Path Board of Directors to help them in their mission to bring together all the platforms, data, and stakeholders needed to fully realize the promise of precision medicine.”
The full press release is available here. Hill’s appointment takes effect immediately.